This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
Second-wave direct-acting antivirals for hepatitis C: Sofosbuvir and Ledipasvir. Lansdale: HAYES, Inc.. Directory Publication. 2014
The second-wave direct-acting antivirals (DAAs) are prescribed to treat chronic hepatitis C with the objective of achieving sustained viral response and preventing harmful liver damage. These agents were developed to address the issues associated with pegylated interferon, ribavirin, and previously approved DAAs, including lack of response and relapse, resistance, poor safety profile, and burdensome treatment regimen. Second-wave DAA agents include simeprevir, sofosbuvir, and the combination of sofosbuvir and ledipasvir.
This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly.
Subject indexing assigned by CRD
Antiviral Agents; Hepatitis C, Chronic; Humans
Country of organisation
An English language summary is available.
Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: email@example.com
Date abstract record published